

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**SECTION 1. IDENTIFICATION**

Product name : LUNSUMIO Vials 30 mg/30 ml
Product code : RO703-0816/F02-04
Common name(s),
synonym(s) of the substance : anti-CD20/CD3 TDB
Bispecific human anti-CD20/CD3 TDB antibody

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
South San Francisco, CA 94080
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone
In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

Not a hazardous substance or mixture.

GHS label elements

Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Mosunetuzumab	1905409-39-3	0.1
.alpha.-D-Glucopyranoside, .beta.-D-	57-50-1	8.2

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

fructofuranosyl		
L-Histidine	71-00-1	0.16
L-Methionine	63-68-3	0.15
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.1
Acetic acid	64-19-7	0.1
Water	7732-18-5	91

SECTION 4. FIRST AID MEASURES

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : No hazardous combustion products are known

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Protect from heat and light

Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protect from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Ampoules, Prefilled syringes, Vials, Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible	Basis

LUNSUMIO Vials 30 mg/30 ml
Version
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

			concentration	
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0
Mosunetuzumab	1905409-39-3	IOEL	0.004 mg/m3	Roche Industrial Hygiene Committee (RIHC)

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Nitrile rubber
 Break through time : > 30 min
 Glove thickness : > 0.11 mm

Material : butyl-rubber
 Break through time : > 480 min
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : General industrial hygiene practice.

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Clear liquid

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 5.8

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Self-ignition : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

LUNSUMIO Vials 30 mg/30 ml

Version 1.0 Revision Date: 06/10/2025 Date of last issue: - Date of first issue: 06/10/2025

Viscosity
Viscosity, dynamic : No data available
Viscosity, kinematic : No data available
Explosive properties : No data available
Oxidizing properties : No data available
Particle characteristics
Particle Size Distribution : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
Chemical stability : Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
Stable under normal conditions.
Possibility of hazardous reactions : No data available
Stable under recommended storage conditions.
No hazards to be specially mentioned.
Conditions to avoid : No data available
No data available
Incompatible materials : No data available
Not applicable
Hazardous decomposition products : No decomposition if stored and applied as directed.
No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified due to lack of data.

Components:**Mosunetuzumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration
Acute toxicity (other routes of administration) : HNSTD (Highest Non-Severely Toxic Dose) (cynomolgus monkey): > 1 mg/kg
Application Route: i.v.
GLP: yes

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

L-Histidine:Acute oral toxicity : LD50 Oral (Rat): > 15,000 mg/kg
LD50 Oral (Mouse): > 15,000 mg/kg**L-Methionine:**Acute oral toxicity : Acute toxicity estimate (Rat): > 5,000 mg/kg
Method: Expert judgment

Acute toxicity estimate (Mouse): > 5,000 mg/kg
Method: Expert judgment

Acute inhalation toxicity : Acute toxicity estimate: > 30 mg/l
Test atmosphere: dust/mist
Method: Expert judgment

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Expert judgment**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Acute oral toxicity : LD50 Oral (Rat): 38,900 mg/kg

Acetic acid:Acute oral toxicity : LD50 Oral (Rat, male and female): 3,310 mg/kg
GLP: no

Acute inhalation toxicity : LC50 (Rat, male and female): 11.4 mg/l
Exposure time: 4 h
Test atmosphere: vapor
GLP: no
Assessment: The substance or mixture has no acute inhalation toxicity

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**Skin corrosion/irritation**

Not classified due to lack of data.

Components:**L-Histidine:**

Species : reconstructed human epidermis (RhE)
Method : OECD Test Guideline 439
Result : No skin irritation
GLP : yes

L-Methionine:

Remarks : This information is not available.

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Species : Rabbit
Result : No skin irritation

Acetic acid:

Species : Rabbit
Exposure time : 4 h
Method : OECD Test Guideline 404
Result : Causes severe burns.
GLP : No information available.

Serious eye damage/eye irritation

Not classified due to lack of data.

Components:**L-Histidine:**

Species : Bovine cornea
Result : No eye irritation
Method : OECD Test Guideline 437

L-Methionine:

Remarks : This information is not available.

LUNSUMIO Vials 30 mg/30 ml

Version 1.0 Revision Date: 06/10/2025 Date of last issue: - Date of first issue: 06/10/2025

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Species : Rabbit
Result : No eye irritation

Acetic acid:

Species : Rabbit
Result : Risk of serious damage to eyes.
Exposure time : 4 h
Method : OECD Test Guideline 405
GLP : No information available.

Respiratory or skin sensitization**Skin sensitization**

Not classified due to lack of data.

Respiratory sensitization

Not classified due to lack of data.

Components:**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Species : Guinea pig
Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Genotoxicity in vitro : Test Type: Micronucleus test
Test system: Escherichia coli
Result: negative

Germ cell mutagenicity - Assessment : Tests on bacterial or mammalian cell cultures did not show mutagenic effects.

Acetic acid:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

Test system: *Salmonella typhimurium*
Metabolic activation: Metabolic activation
Method: OECD Test Guideline 471
Result: negative
GLP: No information available.
Remarks: In vitro tests did not show mutagenic effects

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 473
Result: negative
GLP: no
Remarks: In vitro tests did not show mutagenic effects

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat (male and female)
Application Route: Inhalation
Exposure time: 13 weeks
Dose: 0, 1, 5, 20 ppm
Method: Mutagenicity (micronucleus test)
Result: negative
GLP: yes

Carcinogenicity

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

L-Histidine:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

LUNSUMIO Vials 30 mg/30 ml
Version
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**Acetic acid:**

Species : Mouse, female
 Application Route : Dermal
 Exposure time : 32 weeks
 Result : negative
 GLP : no
 Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified due to lack of data.

Components:**Mosunetuzumab:**

Effects on fertility : Species: cynomolgus monkey
 Result: No adverse effects.

Acetic acid:

Effects on fetal development : Species: Mouse, female
 Application Route: Oral
 Dose: 10 ml/kg body weight
 Duration of Single Treatment: 6 - 15 d
 Developmental Toxicity: NOAEL: 345 mg/kg body weight
 Method: Regulation (EC) No. 440/2008, Annex, B.31
 GLP: No information available.

STOT-single exposure

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**L-Methionine:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

L-Methionine:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration toxicity

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

L-Methionine:

No data available

Further information**Product:**

Remarks : No data available

Components:**Mosunetuzumab:**

Remarks : after parenteral application, rare cases of hypersensitivity, including anaphylactic shock, can occur

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:

Remarks : Health injuries are not known or expected under normal use.

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

L-Histidine:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Test Type: static test
Method: OECD Test Guideline 202
GLP: yes

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
End point: Growth inhibition
Exposure time: 72 h
Test Type: static test
Method: OECD Test Guideline 201
GLP: yes

Toxicity to microorganisms : EC10 (activated sludge): > 200 mg/l
Exposure time: 5 d
GLP: no

L-Methionine:

Toxicity to fish : LC50 : > 100 mg/l
Exposure time: 96 h

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 216 mg/l
Exposure time: 96 h

LUNSUMIO Vials 30 mg/30 ml
Version
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

LC50 (Brachydanio rerio (zebrafish)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 GLP: yes

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOELR (Daphnia): 10 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC0 (Pseudomonas putida): > 10,000 mg/l
 EC50 (Bacteria): 774 mg/l
 Exposure time: 5 h

Acetic acid:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 300.82 mg/l
 End point: mortality
 Exposure time: 96 h
 Test Type: semi-static test
 Analytical monitoring: no
 Method: OECD Test Guideline 203
 GLP: yes

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 300.82 mg/l
 End point: Immobilization
 Exposure time: 48 h
 Test Type: static test
 Analytical monitoring: yes
 Method: OECD Test Guideline 202
 GLP: yes

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 300.82 mg/l
 Exposure time: 72 h
 Test Type: static test
 Analytical monitoring: no
 GLP: yes

Persistence and degradability**Components:****Mosunetuzumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Biodegradability : Result: Readily biodegradable.
 Biodegradation: > 70 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301B

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**Acetic acid:**

Biodegradability : aerobic
Inoculum: activated sludge
Concentration: 3 mg/l
Result: Readily biodegradable.
Biodegradation: 96 %
Exposure time: 20 d
GLP: no

Bioaccumulative potential**Components:****Mosunetuzumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:

Partition coefficient: n-octanol/water : log Pow: -3.7 (68 °F / 20 °C)

L-Histidine:

Partition coefficient: n-octanol/water : log Pow: ca. -3.32

L-Methionine:

Partition coefficient: n-octanol/water : log Pow: -1.87

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Bioaccumulation : Remarks: No data available

Partition coefficient: n-octanol/water : Remarks: No data available

Acetic acid:

Bioaccumulation : Bioconcentration factor (BCF): 3.16

Partition coefficient: n-octanol/water : log Pow: -0.17 (77 °F / 25 °C)
pH: 7
Method: No information available.
GLP: No information available.

Water:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**Other adverse effects****Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : No data available

Components:**Mosunetuzumab:**

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

L-Histidine:

Additional ecological information : No data available

L-Methionine:

Adsorbed organic bound halogens (AOX) : Remarks: Not applicable
Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

LUNSUMIO Vials 30 mg/30 ml
Version
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION
CERCLA Reportable Quantity

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
SARA 311/312 Hazards	: No SARA Hazards	

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid 64-19-7 >= 0 - < 0.1 %

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid 64-19-7 >= 0 - < 0.1 %

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know

Water 7732-18-5

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Acetic acid 64-19-7

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025**Maine Chemicals of High Concern****Vermont Chemicals of High Concern****Washington Chemicals of High Concern****California Permissible Exposure Limits for Chemical Contaminants**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

The ingredients of this product are reported in the following inventories:

AIIC	:	Not in compliance with the inventory
DSL	:	This product contains the following components that are not on the Canadian DSL nor NDSL. Mosunetuzumab
NZIoC	:	On the inventory, or in compliance with the inventory
ENCS	:	Not in compliance with the inventory
ISHL	:	Not in compliance with the inventory
KECI	:	Not in compliance with the inventory
PICCS	:	Not in compliance with the inventory
IECSC	:	Not in compliance with the inventory
TCSI	:	Not in compliance with the inventory
TSCA	:	Product contains substance(s) not listed on TSCA inventory.
TECI	:	Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.


No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION**Further information**

LUNSUMIO Vials 30 mg/30 ml

Version
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

NFPA 704:



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect

LUNSUMIO Vials 30 mg/30 mlVersion
1.0Revision Date:
06/10/2025Date of last issue: -
Date of first issue: 06/10/2025

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/10/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404